Cervical cancer is one of the most common gynecological malignancies diagnosed during pregnancy although, fortunately, it is a rare event. In majority of cases, the management of cervical cancer in pregnant women is not different from nonpregnant women and prognosis seems not compromised by pregnancy. The association between cancer and pregnancy appears to be a significant challenge for women and specialists and the decisions about therapy must be individualized and taken by a multidisciplinary team. This review is focused on cervical cancer in pregnancy. The aim is to discuss the diagnosis, potential biomarkers and molecular aspects, therapeutic approaches, and prognosis from intraepithelial cervical neoplasia to invasive cervical cancer (early and advanced stages) in different gestational ages. We provide an overview of the current literature regarding the treatment strategies of concurrent pregnancy and cervical cancer cases and we propose some clinical advices to help clinicians to manage this condition. A mention about the effects of the conservative therapy (as conization) on fertility, the human papillomavirus vaccine in pregnant women and our center's experience with obstetrical and oncological outcomes are reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcp.28340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Focus Groups With Guatemalan Community Leaders About Barriers to Cervical Cancer Prevention and Control.
Health Promot Pract
January 2025
The University of Utah College of Nursing, Salt Lake City, UT, USA.
Cervical cancer is the leading cause of cancer-related death among Latin American women, including Guatemalans. This is troubling, given we have a vaccine, screening tool, and treatment for this preventable disease. Human papillomavirus (HPV) causes most cervical cancer.
View Article and Find Full Text PDFSurgical Advancements, Immunotherapy, Targeted and Conventional Therapies, Biopsy, Colposcopy, and Pap Smear Integration in the Management of Cervical Cancer.
Curr Med Chem
January 2025
Department of Pharmaceutical Quality Assurance, SVKM Institute of Pharmacy, Dhule, 424001, India.
Cervical cancer remains a significant global health concern, making it essential to investigate new treatment options continuously. This page provides an overview of the latest advancements and best practices in detection and intervention, including Pap smears, colposcopy, biopsy, immunotherapy, targeted therapies, chemotherapy, radiation therapy, and surgery. Surgical techniques such as radical hysterectomy and minimally invasive procedures have advanced to enhance patient outcomes and quality of life.
View Article and Find Full Text PDFResults comparison of cervical cancer early detection using cerviray ® with VIA test.
BMC Res Notes
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Objectives: This study investigates the performance of artificial intelligence (AI) technology, namely Cerviray AI, compared with Cerviray expert, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC). The Visual Inspection with Acetic Acid (VIA) test is used as the gold standard.
Results: The study involved 44 patients from various health centers in West Java Province.
Perceptions of cervical screening uptake amongst South Asian women in Ontario, Canada: a concept mapping study.
BMC Public Health
January 2025
University of Toronto, 155 College St Room 500, Toronto, ON, M5T 3M7, Canada.
Background: Regular cervical screening can significantly reduce the onset and prevalence of cervical cancer. In Ontario, Canada, South Asian women have the lowest rates of cervical cancer screening among major ethnic groups in the province.
Methods: Using an innovative and participant-driven method called Concept Mapping (CM), we set out to understand how the lives and experiences of South Asian women living in Ontario shape their decisions around getting screened for cervical cancer.
Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study.
Arthritis Res Ther
January 2025
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea.
Background: To investigate cancer incidence and the potential influence of immunosuppressive agents in Korean systemic lupus erythematosus (SLE) patients.
Methods: We conducted a retrospective analysis utilizing data from the Korea Healthcare Bigdata Linked Platform, which integrated the National Central Cancer Registry and National Health Insurance Service databases covering the period 2008-2017. Incidence rates (IRs) per 10,000 person-years (PYs) for site-specific cancers of SLE patients were calculated using ICD-O-3 codes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!